OncoCyte (NASDAQ:OCX) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement. Analysts estimate that OncoCyte will ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded ...

Oncocyte Corp., a diagnostics technology company, plans to use $29.1 million in new funds to drive development and commercialization efforts of its transplant assay. The company’s five largest ...

IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results ...

Management reiterated that they are on track to submit their FDA package by the end of 2025, consistent with prior communications. The target remains FDA approval in the first half of 2026. The goal ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. In their previous filing dated July 28, 2022 they ...

Appoints diagnostic industry veteran and current Board member Ronald Andrews, Jr. as Chief Executive Officer Outgoing CEO William Annett to serve as an advisor to the Company Company to host ...

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA ...

Oncocyte’s technologies may provide more precision to the selection of appropriate immune therapies and monitoring for treatment response in real time allowing physicians to personalize treatment more ...

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look ...

ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, ...